Skip to main content Accessibility help
×
Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-23T03:44:07.889Z Has data issue: false hasContentIssue false

21b - Considerations Regarding the Pharmacological Management of Personality Disorders: Commentary on Recent Developments in the Pharmacologic Management of Personality Disorders

from Part V - Treatment

Published online by Cambridge University Press:  24 February 2020

Carl W. Lejuez
Affiliation:
University of Kansas
Kim L. Gratz
Affiliation:
University of Toledo, Ohio
Get access

Summary

Despite the advancements in the development of pharmacological interventions for personality disorders (PDs), clinicians should be relatively cautious about the potential benefits of using pharmacological agents for the treatment of PDs when facing therapeutic decisions for individual patients. The pharmacological management of PDs is considerably complex; frequent treatment drop-out, non-compliance, and adverse effects illustrate why having a good therapeutic relationship with patients is a particularly important factor for the success of pharmacological treatment of PDs. Results from clinical trials for PDs may not be generalizable for individual patients in the community. PDs are heterogeneous conditions associated with many psychiatric disorders. Yet, clinical trials frequently include highly selected populations that do not necessarily correspond to typical patients with PDs found in community settings. Considering that PDsfrequently co-occur with other psychiatric diagnoses, a promising approach to future research in PDs should consider the development of treatment algorithms based on co-occurring disorders. This approach is likely to resonate with prescribing physicians trained to evaluate patients systematically for the presence or absence of specific disorders. For instance, this approach has been increasingly studied in gambling disorder, with promising findings reported thus far.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington, DC: American Psychiatric Association.Google Scholar
American Psychiatric Association. (2001). Practice guideline for the treatment of patients with borderline personality disorder. American Journal of Psychiatry, 158, 152.Google Scholar
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.Google Scholar
Arntz, A., Van den Hoorn, M., Cornelis, J., Verheul, R., van den Bosch, W. M., & de Bie, A. J. (2003). Reliability and validity of the borderline personality disorder severity index. Journal of Personality Disorders, 17, 4559.CrossRefGoogle ScholarPubMed
Bateman, A. W., Gunderson, J., & Mulder, R. (2015). Treatment of personality disorder. Lancet, 385, 735743.CrossRefGoogle ScholarPubMed
Bellino, S., Paradiso, E., Bozzatello, P., & Bogetto, F. (2010). Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: A pilot study. Journal of Psychopharmacology, 24, 333339.CrossRefGoogle ScholarPubMed
Bernstein, D. P., Iscan, C., & Masner, J. (2007). Opinions of personality disorder experts regarding the DSM-IV personality disorders classifications system. Journal of Personality Disorders, 21(5), 536551.CrossRefGoogle Scholar
Black, D. W., Zanarini, M. C., Romine, A., Shaw, M., Allen, J., & Schulz, S. C. (2014). Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: A randomized, double-blind, placebo controlled trial. American Journal of Psychiatry, 171(11), 11741182.Google Scholar
Bullock, S. A., & Potenza, M. N. (2012). Pathological gambling: Neuropsychopharmacology and treatment. Current Psychopharmacology, 1(1), 6785.CrossRefGoogle ScholarPubMed
de Brito, A. M., de Almeida Pinto, M. G., Bronstein, G., Carneiro, E., Faertes, D., Fukugawa, V., … Tavares, H. (2017). Topiramate combined with cognitive restructuring for the treatment of gambling disorder: A two-center, randomized, double-blind clinical trial. Journal of Gambling Studies, 33(1), 249263.CrossRefGoogle ScholarPubMed
Grant, J. E., Odlaug, B. L., Chamberlain, S. R., Potenza, M. N., Schreiber, L. R., Donahue, C. B., & Kim, S. W. (2014). A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. Journal of Clinical Psychiatry, 75(1), 3945.CrossRefGoogle ScholarPubMed
Grant, J. E., Potenza, M. N., Kraus, S. W., & Petrakis, I. L. (2017). Naltrexone and disulfiram treatment response in veterans with alcohol dependence and co-occurring problem-gambling features. Journal of Clinical Psychiatry, 78(9), e1299e1306.CrossRefGoogle ScholarPubMed
Houghton, D. C., Capriotti, M. R., De Nadai, A. S., Compton, S. N., Twohig, M. P., Neal-Barnett, A. M., … Woods, D. W. (2015). Defining treatment response in trichotillomania: A signal detection analysis. Journal of Anxiety Disorder, 36, 4451.Google Scholar
Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D.S., Quinn, K., … Wang, P. (2010). Research domain criteria (RDoC): Toward a new classification framework for research mental disorders. American Journal of Psychiatry, 167(7), 748751.CrossRefGoogle Scholar
Joyce, D. W., Kehagia, A. A., Tracy, D. K., Proctor, J., & Shergill, S. S. (2017). Realising stratified psychiatry using multidimensional signatures and trajectories. Journal of Translational Medicine, 15, 15. doi:10.1186/s12967-016-1116-1CrossRefGoogle ScholarPubMed
Joyce, D. W., Tracy, D. K., & Shergill, S. S. (2017). Are we failing clinical trials? A case for strong aggregate outcomes. Psychological Medicine, 48(2), 177186.CrossRefGoogle ScholarPubMed
National Institute for Health and Care Excellence, UK [NICE]. (2015). Borderline Personality Disorder: Recognition and Management. www.nice.org.uk/guidance/cg78/resources/borderline-personality-dosrder-recognition-and-management-pdf-975635141317Google Scholar
Newcomer, J. W. (2007). Antipsychotic medications: Metabolic and cardiovascular risk. Journal of Clinical Psychiatry, 68(4), 813.Google ScholarPubMed
Ornoy, A. (2009). Valproic acid in pregnancy: How much are we endangering the embryo and fetus? Reproductive Toxicology, 28(1), 110.Google Scholar
Rohde, C., Polcwiartek, C., Correll, C. U., & Nielsen, J. (2017). Real-world effectiveness of clozapine for borderline personality disorder: Results from a 2-year mirror-image study. Journal of Personality Disorders, 31, 115.Google Scholar
Ten Have, M., Verheul, R., Kaasenbrood, A., van Dorsselaer, S., Tuithof, M., & Kleinjan, M. (2016). Prevalence rates of borderline personality disorder symptoms: A study based on the Netherlands Mental Health Survey and Incidence Study–2. BMC Psychiatry, 16, 249.CrossRefGoogle ScholarPubMed
Trull, T. J., Tragesser, S. L., Solhan, M., & Schwartz-Mette, R. (2007). Dimensional models of personality disorder: Diagnostic and Statistical Manual of Mental Disorders Fifth Edition and beyond. Current Opinion in Psychiatry, 20(1), 5256.CrossRefGoogle ScholarPubMed
Walker, M., Toneatto, T., Potenza, M. N., Petry, N., Ladouceur, R., Hodgins, D. C., … Blaszczynski, A. (2006). A framework for reporting outcomes in problem gambling treatment research: The Banff, Alberta Consensus. Addiction, 101(4), 504511.Google Scholar
Widiger, T. A., & Trull, T. J. (2007) Plate tectonics in the classification of personality disorder: Shifting to a dimensional model. American Psychologist, 62(2), 7183.CrossRefGoogle ScholarPubMed
Wright, A. G. C., Hallquist, M. N., Morse, J. Q., Scott, L. N., Stepp, S. D., Nolf, K. A., & Pilkonis, P. A. (2013). Clarifying interpersonal heterogeneity in borderline personality disorder using latent mixture modeling. Journal of Personality Disorder, 27(2), 125143.CrossRefGoogle ScholarPubMed
Zanarini, M. C., Schulz, S. C., Detke, H. C., Tanaka, Y., Zhao, F., Lin, D., … Corya, S. (2011). A dose comparison of olanzapine for the treatment of borderline personality disorder: A 12-week randomized, doubleblind, placebo-controlled study. Journal of Clinical Psychiatry, 72, 13531362.CrossRefGoogle ScholarPubMed
Zanarini, M. C., Vujanovic, A. A., Parachini, E. A., Boulanger, J. L., Frankernburg, F. R., & Hennen, J. (2003). Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): A continuous measure of DSM-IV borderline psychopathology. Journal of Personality Disorders, 17(3), 233242.Google Scholar
Zanarini, M. C., Weingeroff, J. L., Frankenburg, F. R., & Fitzmaurice, G. M. (2015). Development of the self-report version of the Zanarini Rating Scale for Borderline Personality Disorder. Personality and Mental Health, 9(4), 243249.Google Scholar
Zimmerman, M., & Mattia, J.I. (1999). Axis I diagnostic comorbidity and borderline personality disorder. Comprehensive Psychiatry, 40(4), 245252.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×